Tag: Ph+ CML treatment options

Home / Ph+ CML treatment options

Categories

Bosutinib is approved by the FDA for pediatric patients with chronic myelogenous leukemia

Nov 2023: For paediatric patients aged one year and above with chronic phase (CP) Ph+ chronic myelogenous leukaemia (CML), either newly diagnosed (ND) or resistant or intolerant (R/I) to previous the...
ph-cml-treatment-options

Scan the code